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NUCLEOTIDE OR NUCLEOSIDE 
PHOTOAFFINITY COMPOUND MODIFIED 
ANTIBODIES, METHODS FOR THEIR 
MANUFACTURE AND USE THEREOF AS 
DIAGNOSTICS AND THERAPEUTICS 
This application is a divisional. of Application Ser. No. 
08/208.822?led Mar. 11. 1994 now U.S. Pat. No. 5.596.081. 
CROSS REFERENCE TO RELATED 
APPLICANTS 
This application relates to U.S. Ser. No. 081138.109 ?led 
on Oct. 20. 1993. This application is incorporated by refer 
ence in is its entirety herein. 
FIELD OF THE INVENTION 
The present invention relates to the discovery of novel site 
or sites on antibodies having high affinity for nucleotide or 
nucleoside photoa?inity compounds. The present invention 
further relates to the use of these novel site or sites as a target 
for photoa?inity labeling using nucleotide or nucleoside 
photoa?inity compounds and for the attachment of mol 
ecules having a particular chemical or biological activity. In 
particular. the present invention concerns a site or sites on 
antibodies having high a?inity for purine or purine deriva 
tive containing photoa?inity compounds. e. g.. ATP- or G1? 
analog photoat?nity compounds and the use of these sites as 
targets for purine or purine derivative photoa?inity com 
pounds or other heterocyclic base containing compounds 
which have a?inity for these sites and for the attachment of 
molecules having a particular chemical or biological activ 
ity. 
The present invention further relates to compositions, 
methods. and test kits which contain or use the subject 
nucleotide photoa?inity labeled antibodies. The present 
invention still further relates to novel compositions, methods 
and test kits which use the procedure of photoa?inity label 
ing with nucleotide a?inity probes, to attach molecules 
having a desired chemical or biological activity to antibody 
molecules. 
BACKGROUND OF THE INVENTION 
Antibodies are speci?c immunoglobulin molecules pro 
duced by vertebrate immune systems in response to chal 
lenge by foreign proteins. glycoproteins. cells, or other 
typically foreign substances. The sequence of events which 
permits an organism to overcome invasion by foreign cells 
or to rid the system of foreign substances is at least partially 
understood. An important part of this process is the manu 
facture of antibodies which bind speci?cally to a particular 
foreign antigenic substance. The binding speci?city of such 
polypeptides to a particular antigen is highly re?ned, and the 
multitude of speci?cities capable of being generated by an 
individual vertebrate is remarkable in its complexity and 
variability. Thousands of antigens are capable of eliciting 
antibody responses. each almost exclusively directed to the 
particular antigen which elicited it. 
Immunoglobulins include both antibodies. as above 
described. and analogous protein substances which lack 
antigen speci?city. The latter are produced at low levels by 
the lymph system and in increased levels by myelomas. 
Antibodies are produced by B lymphocytes and represent 
the humoral arm of the immune defense system. Because of 
their antigen speci?city. antibodies comprise numerous 
diagnostic and therapeutic applications. For example. they 
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can be used as speci?c immunoprecipitating agents to detect 
the presence of an antigen which they speci?cally bind by 
coupling the antigen-antibody reaction with suitable detec 
tion techniques such as labeling with radioisotopes or with 
detectable enzymes (RIA. EMIT. and ELISA). Antibodies 
are thus the foundation of immunodiagnostic tests for many 
antigenic substances. 
Another important application of antibodies involves their 
use as therapeutics. The therapeutic administration of anti 
bodies has recently been described for the treatment of 
numerous disease conditions including cancer. and numer 
ous infectious diseases. 
The therapeutic usage of antibodies has been the focus of 
greater interest since the development of monoclonal 
antibody/hybridoma technology by Kohler and Milstein 
(Proc. Natl. Acad. Sci. USA, 772197 (1980)). Monoclonal 
antibodies. which are produced by hybridomas. are prefer 
able to polyclonal antibodies because of their greater anti 
genic speci?city. Monoclonal antibodies have a lesser ten 
dency than polyclonal antibodies to non-speci?cally bind to 
non-targeted moieties. e.g.. cells which do not express the 
corresponding antigen. However. monoclonal antibodies 
still suffer from some disadvantages. e.g.. they tend to be 
contaminated with other proteins and cellular materials of 
hybridoma (mammalian) origin. Also. hybridoma cell lines 
tend to be unstable and may alter the production of the 
antibody produced or stop secreting the antibody altogether. 
In an effort to obviate some of the problems associated 
with polyclonal and monoclonal antibodies. and further to 
obtain a reproducible supply of antibodies having a de?ned 
binding speci?city. researchers have used recombinant tech 
niques to produce immunoglobulins which are analogous or 
modified in comparison to antibodies normally found in 
vertebrate systems. For example. U.S. Pat. No. 4.816397 
issued on Mar. 28. 1989 to Boss et al. and U.S. Pat No. 
4.816.567 issued on Mar. 28. 1989 to Cabilly et al. disclose 
recombinant immunoglobulins and immunoglobulin 
fragments. and methods for their production. 
To enhance or modify the properties of recombinant 
antibodies. it is further known to produce mutant or chimeric 
antibodies, e.g.. which comprise sequences from several 
di?erent mammalian species or bispeci?c antibodies which 
comprise antigenic binding sequences from two ditferent 
antibodies. For example. humanized antibodies which com 
prise antigen-binding sites from a non-human species 
(typically routine) but wherein the remainder of the immu 
noglobulin is of human origin are known in the art. and have 
been reported to have signi?cant potential as therapeutics 
because of their reduced antigenicity. It is further known to 
produce recombinant antibodies of single chain form. which 
completely lack constant domain sequences but which bind 
antigen. (See, Bird et al.. Science, 242. 423-426 (1988)). 
In order to increase the e?icacy of antibody molecules as 
diagnostic or therapeutic agents. it is conventional to 
covalently bind or complex desired molecules thereto. in 
particular e?’ector or reporter molecules. Eifector molecules 
essentially comprise molecules having a desired activity. 
e.g.. cytotoxic activity. By contrast. a reporter molecule is 
de?ned as any moiety which may be detected using an assay. 
Examples of effector molecules which have been attached to 
antibodies include by way of example. toxins. anti-tumor 
gents. therapeutic enzymes. radionuclides. antiviral agents. 
chelating agents. cytokines. growth factors. and polynucle 
otides. Examples of reporter molecules which have been 
conjugated to antibodies include. by way of example. 
enzymes. radiolabels. ?uorescent labels. phosphorescent 
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molecules. chemiluminescent molecules. chromophores, 
luminescent molecules. and colored particles. 
While it is desirable to attach molecules to antibodies in 
order to impart a desired activity to the antibody or provide 
for the detection thereof, the attachment of desired mol 
ecules to antibodies is not always possible to carry out 
conveniently. or effectively, because such attachment may 
result in loss of antibody activity. In particular, current 
methods for generating radiolabeled antibodies for diagnos 
tic and therapeutic use suffer from such limitations. For 
example. the ratio of target-speci?c versus non-speci?c 
uptake of radiolabeled antibodies used in tumor imaging is 
often low. resulting in unclear images or missing tumor sites. 
Moreover. the low therapeutic index of radiolabeled anti 
bodies limits the use of high radiation doses in radiation 
therapy. 
The underlying reason for such problems is largely 
because the labeling chemistry for introduction of the radio 
label results in the partial denaturation of the antibody 
structure. which in turn causes the antibodies to aggregate in 
vivo or in vitro. Aggregated and damaged immunoglobulins 
are recognized by scavenger cells in the body, such as 
macrophages and Kupffer cells in the liver and lung. 
Another problem is that most coupling strategies result in 
non site-speci?c attachment of the molecule to the antibody 
molecule. in particular. attachment may occur at antibody 
residues which are essential for antigen binding or other 
antibody functions. For instance, a known site of attachment 
of desired molecules to antibody molecules comprise thiol 
groups. since thiol groups occur naturally in proteins as 
cysteine residues. However, such residues are relatively 
uncommon. are often inside the molecule and are frequently 
involved in forming disul?de bridges within or between 
protein molecules. Thus. there is a danger that if a naturally 
occm-ring cysteine residue is used as a site of attachment. it 
will interfere with the normal folding and stabilization of the 
antibody protein. 
In an eifort to obviate such problems, alternative strate 
gies have been developed which provide for site-selective 
attachment of a desired molecules to antibodies. without loss 
of antigen-binding activity. For example, it is known to 
produce recombinant antibodies comprising cysteine resi 
dues introduced into their surface structure to provide a thiol 
group which is available for covalent binding to an etfector 
or reporter molecule. This method has been reported to 
facilitate the site-speci?c attachment of desired molecules 
without loss of antigen binding properties. (See. U.S. Pat. 
No. 5.219.996 issued on Jun. 15, 1993 to Bodmer et al.) 
However, this is not always possible or convenient since it 
obviously requires the possession of a recombinant DNA 
encoding the particular antibody. 
It has further been proposed to derivatize immunoglobu 
lins by selectively introducing sulfhydryl groups in the Fc 
region of an immunoglobulin. using reaction conditions 
which purportedly do not result in alteration of the antibody 
combining site. Antibody conjugates produced according to 
this methodology are disclosed to exhibit improved 
longevity, speci?city and sensitivity (U.S. Pat. No. 5.196, 
066 issued on Mar. 2. 1993 to Bieniarz et al.). 
Site-speci?c attachment of e?ector or reporter molecules. 
wherein the reporter or eifector molecule is conjugated to a 
carbohydrate residue in the Fc region has also been dis 
closed in the literature. (See. e.g., O’Shannessy et al.. J. 
i'mmun. Meth., 99. 153-161 (1987)). This approach has been 
reported to produce diagnostically and therapeutically prom 
ising antibodies which are currently in clinical evaluation. 
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Another known method of site-speci?c attachment of 
molecules to antibodies comprises the reaction of antibodies 
with hapten-based a?inity labels. Essentially. hapten-based 
a?inity labels react with amino acids in the antigen binding 
site. thereby destroying this site and blocking speci?c anti 
gen reaction. However. this is disadvantageous since it 
results in loss of antigen binding by the antibody conjugate. 
Thus. based on the foregoing. it is clear that there still 
exists a signi?cant need in the an for improved methods of 
attaching molecules to antibodies, in particular elfector or 
reporter molecules, which are site-speci?c and which more 
over result in antibody conjugates having substantially unal 
tered structure and biological activity. most especially anti 
gen binding activity. 
Molecules containing azido groups have been shown to 
form covalent bonds to proteins through reactive nitrene 
intermediates. generated by low intensity ultraviolet light. 
Potter & Haley, Meth. in EnzymoL, 91.613-633 (1983). In 
particular, 2- and 8- azido analogues of purine nucleotides 
have been used as site directed photoprobes to identify 
nucleotide binding proteins in crude cell extracts. Owens & 
Haley, J. Biol. Chem, 259:14843-14848 (1987); Atherton et 
al., Biol. of Reproduction, 32, 155-171 (1985). The 2— and 
8-azido nucleotides have also been used to map nucleotide 
binding domains of puri?ed proteins. Khatoon et al.. Ann. of 
Neurology, 26. 210-219 (1989); King et al.. J. Biol. Chem, 
269, 10210-10218 (1989); and Dholakia et al.. J. Biol. 
Chem, 264. 20638-20642 (1989). 
Photoa?inity probes have been used to determine speci?c 
nucleotide binding sites on a biologically active recombinant 
peptide molecule. Campbell et al.. PNAS. 87, 1243-1246 
(1990). The probes have also been used to study enzyme 
kinetics of puri?ed proteins. Kim et al.. J. Biol. Chem, 265. 
3636-3641 (1990). 
Recently, ATP or GTP analog photoa?inity labeled probes 
have been used to detect a glutarnine synthetase nucleotide 
binding protein having an apparent molecular weight of 
about 42.000 proteins to aid in the diagnosis of Alzheimer’s 
disease in a mammal. U.S. Ser. No. 08/138,109 ?led on Oct. 
20, 1993 by Haley et al. Additionally. ATP or GTP analog 
photoa?inity-labeling reagents have been disclosed for use 
in the detection of particular nucleotide binding proteins to 
aid in the diagnosis of cancer in a mammal and in the 
diagnosis of leukemia in a mammal. (Id.) 
However, while it had been previously lcnown to use 
nucleotide photoa?inity probes, and speci?cally purine con 
taining photoaf?nity analogs (GI‘P- and ATP-analogs). to 
map nucleotide binding domains of puri?ed proteins and to 
identify speci?c nucleotide binding sites on recombinant 
peptide molecules, the use of nucleotide photoaf?nity probes 
to label antibodies has not been previously reported in the 
literature. This is essentially because it had not been previ 
ously known that antibody molecules comprise nucleotide 
photoa?inity sites, and in particular. sites having high a?in 
ity for purine, azidopurine and other similar heterocyclic 
bases. which may be e?iciently photolabeled using appro 
priate photoa?nity probes. 
OBJECT S AND SUMMARY OF THE 
INVENTION 
It is. therefore, an object of this invention to identify 
nucleotide or nucleoside a?inity sites on antibodies which 
provides for the site speci?c photoinsertion of desired mol 
ecules to antibodies. It is further a speci?c object of the 
invention to characterize the effects of these a?inity sites on 
antibody function. 
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It is a more speci?c object of this invention to identify a 
site or sites on antibodies having high a?inity for purines, 
azido-purines and other similar heterocyclic organic 
compounds, in particular ATP- or GTP-analog photoa?inity 
compounds. 
It is another speci?c object of the invention to provide 
methods for coupling desired molecules. e.g., e?’ector or 
reporter molecules to an antibody by site-speci?c attachment 
of the molecules to nucleotide a?inity site or sites contained 
on the antibody molecule or by attachment of the molecules 
to a nucleotide photoat?nity compound which has been 
photoinserted at said nucleotide a?inity site. 
It is a more speci?c object of the invention to provide 
methods for site-speci?cally photoai?nity coupling a purine. 
azidopurine or similar heterocyclic base containing 
compound. in particular an ATP- GTP-analog photoa?inity 
compound. which compound is attached to one or more 
molecules having a desired activity, to a site or sites con 
tained on the antibody molecule having high a?inity for 
purine. azidopurine or other similar heterocyclic bases, or to 
preferably an ATP- or GTP-analog photoa?inity compound. 
which as been photoinserted onto said site or sites. 
It is another object of the invention to provide antibodies 
conjugated to desired molecules, in particular. etfector or 
reporter molecules wherein such molecules are site 
speci?cally attached to the antibody via a nucleotide a?inity 
site. or to a nucleotide photoa?inity analog attached to said 
site. 
It is a more speci?c object of the invention to provide 
antibodies conjugated to desired molecules. in particular, 
reporter or effector moieties wherein such ligands are 
attached to the antibody at a site having high a?inity for 
purine, azidopurine and other similar heterocyclic bases, in 
particular ATP- or GTP-analog photoa?inity compounds, or 
to a nucleotide photoa?inity compound attached to said site. 
It is another object of the invention to provide a method 
for photoa?inity labeling of antibodies by the attachment of 
nucleotide photoa?inity probes to a nucleotide a?inity site or 
sites contained on the irnmunoglobulin molecule. It is a 
more speci?c object of the invention to provide a method for 
photoa?inity labeling of antibodies by the attachment of a 
labeled purine, azidopurine or other similar heterocyclic 
base containing photoa?inity probe, and in partiurlar an 
ATP- or GTP-analog photoa?inity labeled compound to a 
site or sites on the antibody having high a?inity of purine, 
azidopurine and/or similar heterocyclic bases, and in par 
ticular A'I'P- or G'I’P-analog photoat?nity compounds. 
It is another objeat of the invention to provide photoaf 
?nity labeled antibodies and compositions containing, 
wherein such antibodies have been coupled to a nucleotide 
photoa?inity probe via a nucleotide a?‘inity site contained on 
the antibody molecule. 
It is a more speci?c object of the invention to provide 
photoa?inity labeled antibodies and compositions 
containing, wherein such antibodies have been coupled to a 
labeled purine, azidopurine and/or similar heterocyclic base 
containing photoa?inity probe, in particular a labeled ATP 
or GTP-analog photoaf?nity compound, at a site or sites on 
the antibodies having high a?inity for purine, azidopurine 
and/or heterocyclic bases. 
It is another object of the invention to provide improved 
methods of immunodetection of an antigen. wherein such 
methods include the detection and/or quanti?cation of 
antigen-antibody complexes using a labeled antibody 
wherein the improvement comprises using as the labeled 
antibody a nucleotide or nucleoside photoa?inity compound 
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labeled antibody, in particular a labeled purine or purine 
derivative containing compound labeled antibody. and more 
particularly a labeled ATP- or GTP-analog photoa?inity 
compound antibody. 
It is another object of the invention to provide improved 
immunotherapeutics, wherein such irnmunotherapeutics 
comprise an antibody conjugated or complexed to molecules 
having therapeutic or cytotoxic activity, wherein the 
improvement comprises using as the irnmunoconjugate an 
antibody which comprises one or more therapeutic or cyto 
toxic molecules site-speci?cally attached to the antibody via 
a nucleotide or nucleoside a?inity site on the antibody. In the 
preferred embodiment, the a?inity site will have high a?inity 
for purine derivatives. in particular ATP- or GTP-analog 
photoa?inity compounds. The present invention further pro 
vides methods of using said irnmunotherapeutics to treat 
various disease conditions, and as imaging agents. 
It is another object of the invention to provide test lrits for 
detection of antigens comprising diagnostically e?’ective 
mounts of one or more of the following: antibodies. nucle 
otide photoa?‘inity probe. preferably an ATP- or GTP-analog 
photoa?inity compound. reporter. any substrate(s) necessary 
for the detection of the particular reporter. and diagnostic 
carriers. and wherein the various moieties may be separate 
from one another or may be in various forms of attachment. 
It is a more specific object of the invention to provide test 
kits for detection of antigens comprising diagnostically 
eifective mounts of one or more of the following: antibodies. 
a purine, azidopurine and/or a similar heterocyclic base 
containing photoa?inity probe. reporter, any substrates nec 
essary for the detection of the reporter and diagnostic 
carriers. wherein the various moieties may be separate or 
may be in various forms of attachment. 
It is yet another speci?c object of the invention to attach 
heavy metals to antibodies which may or may not be 
radioactive, in particular, ttiphosphate chelated heavy metals 
such as 111In:“by reacting said chelated heavy metals with 
nucleotide photoat?nity compounds before or after such 
nucleotide photoai?nity compounds are attached to a nucle 
otide a?inity site or sites contained in an antibody molecule. 
Other suitable heavy metals for photoattachment include. 
e.g., mercury and iron. In the preferred embodiment. the 
nucleotide photoaf?nity compound will comprise a purine. 
azidopurine and/or a similar heterocyclic base containing 
compound. and most preferably will comprise ATP- or 
GTP-analog photoa?inity compounds. 
It is yet another speci?c object of the invention to provide 
a novel method of attaching nucleic acids to antibodies. e.g.. 
antisense nucleic acids, DNA, RNA or mixtures thereof, 
comprising attaching said nucleic acids to the antibody 
molecule using a nucleotide a?inity compound. preferably a 
purine, azidopurine or similar heterocyclic base containing 
nucleotide ai?nity compound, more particularly an AI'P- or 
GTP-analog photoa?inity compound which comprises a 
highly negatively charged phosphate (tri or tetraphosphate) 
having high at?nity for positively charged polylysine. 
It is a more speci?c object of the invention to attach 
desired molecules. e.g., reporter. or effector molecules 
which contain one or more reactive amino groups. or which 
have been attached to a spacer comprising one or more 
reactive amino groups, to an antibody by reacting same with 
a nucleotide a?inity compound having a reactive cis-hydroyl 
group containing n'bose moiety, which cis-hydroyl group 
may be convened to a dialdehyde under gentle conditions. 
and wherein such attachment may be etfected before or after 
the nucleotide a?nity probe is attached to an antibody via 
nucleotide a?inity site or sites contained on the antibody. 
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BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a graph which compares the photoincorporation 
of ['fZP]-8-N3A'I'P into the heavy and light chains of the 
SIC5 monoclonal antibody wherein the extent of photoin 
corporation is quanti?ed by liquid scintillation counting. 
The results show that the radioactive probe covalently 
attached to both heavy and light chains. 
FIG. 2 is a graph which compares the photoincorporation 
of HJZPB-NBATP into the heavy and light chain sof the 
SIC5 monoclonal antibody in the presence of increasing 
quantities of ATP wherein photoincorporation is quanti?ed 
by liquid scintillation counting. The results indicate that 
50% inhibition occurs at about 350 |.|M. 
FIG. 3 is a bar graph which co ares the percent inhi 
bition of photoincorporau'on of [ 2P]-8-N3ATP into the 
SIC5 monoclonal antibody by oligonucleotides of different 
lengths. Le. a 2A-mer. a 30-mer. a 33-mer and a 58-mer, 
wherein photoincorporation is again determined by liquid 
scintillation counting. The bar graph shows that there is 
much greater inhibition with larger oligonucleotides. 
FIG. 4 is a graph of the results of a solid phase binding 
assay [ELISA] which compares the ability of different 
amounts of unlabeled 3H1 monoclonal antibody (ranging 
from 0 to 10 M) to inhibit binding of the same amount of 
[f2P]-8-N3ATP labeled 3H1 monoclonal antibody to the 
corresponding idiotypic antibody, and wherein the SD10 
antibody is used as a non-speci?c cold (unlabeled) inhibitor. 
Photoincorporation is again quanti?ed by liquid scintillation 
counting. The results show that cold (unlabeled) 3H1 mono 
clonal antibody inhibits binding of the labeled 3H1 antibody. 
FIG. 5 is a bar graph which compares the ability of 
different amounts of unlabeled SD10 monoclonal antibody 
(5.0. 1.0. 0.5 pg) to inhibit binding of the same amount of 
[Y'QPLS-NSATP labeled 5D 10 monoclonal antibody to live 
DHIA- human lymphoma tumor cells. 
FIG. 6 is a photograph of the isoelectric focussing pattern 
of unlabeled and ["{32P]-8-N3ATP labeled SIC5 monoclonal 
antibody. wherein the SIC5 antibody is photolabeled using 
increasing concentrations of [f2P]-8-N3ATP. The isoelec 
tric focussing standards are A=cytochrome C(pI 9.6), 
B=equine myoglobin (pI 7.0). C=bovine carbonic anhydrase 
(pI 6.0). D=phycocyanin (pI 4.65) (lane 10). The unlabeled 
SIC5 antibody is in lane 1. The [f2P]-8-N3AI'P labelled 
SIC5 antibody are as follows: 3.25 M (lane 9), 6.25 |.|M 
(lane 8). 12.5 pin (lane 7). 25|JM (lane 6). 50M (lane 5). 
100 pM (lane 4). 200 pM (lane 3), 400 pM (lane 2). 
FIG. 7 is a photograph of an autoradiograph made from an 
SDS-PAGE on which different antibodies which had been 
photolabeled with ['y“P]-8-N3ATP were separated. In 
particular. autoradiograph shows separation of a murine 
monoclonal IgGl antibody. SD10 monoclonal antibody 
(lane 1), murine myeloma IgGl (lane 2). murine myeloma 
IgA (lane 3), goat Ig (lane 4), goat (Fab)2 fragments (lane 5), 
human myeloma IgGlK (lane 6), human myeloma IgGl 
(lane 7). human myeloma IgM (lane 8). murine monoclonal 
IgM (lane 9) and murine monoclonal IgG2b. SIC5 (lane 10) 
which had photolyzed in the presence of 200 pM {Wm-s 
NsATP and were separated by 55-16% gradient SDS-PAGE, 
stained with Coomassive Blue. dried and autoradiographed. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS OF THE 
INVENTION 
The present invention provides the discovery that some. if 
not all. antibodies contain one or more photoa?inity sites 
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which provide for the selective site-speci?c attachment of 
photoa?nity compounds thereto. In particular. it has been 
discovered that antibodies comprise one or more sites hav 
ing high af?nity for purines. azido-purines and other similar 
heterocyclic organic compounds. and speci?cally ATP- or 
GTP-analogs. However, the present inventors do not wish to 
be limited to purine or azidopurine binding sites. since, 
given the teachings in this application. other photoa?inity 
binding sites may further be identi?ed, e.g.. by reaction of 
antibodies with non-purine containing photoa?inity 
compounds. e. g., pyrimidine derivatives such as photoactive 
analogs of dUTP. including 5-azido-2'-deoxyuridine 
5'-triphosphate (5 -N3dUTP). 
The purine or azidopurine nucleotide a?inity site will 
hereinafter be referred to as the “purine ring binding” or 
simply the “PRB" domain or site. 
The PRB site on antibody molecules was discovered after 
it was found by the present inventors that photoa?inity 
compounds. in particular purine or azidopurine photoa?inity 
compounds readily attach to antibodies and antibody frag 
ments by a photoactivated chemical reaction which occurs 
under mild. physiological conditions. Speci?cally, it has 
been discovered that antibodies comprise one or more PRB 
sites which exhibit such a high a?inity for purines and 
azidopurine photoa?inity analogs, that reaction of antibodies 
with purine and azidopurine photoa?inity analogs under 
mild. physiological conditions. and more particularly after 
only a single 2-5 minute photolysis results in nearly 100% 
photoattachment. 
This is in contrast to the harsh and potentially damaging 
conditions which are generally required to facilitate the 
elfective covalent attachment of desired molecules to anti 
bodies. Thus. the present invention provides an improved 
method for the attachment of desired molecules to 
antibodies. since it utilizes reaction conditions which are 
more compatible with the preservation of labile biological 
molecules and living cells. 
However, it should be emphasized that while the condi 
tions which facilitate the attachment of nucleotide photoaf 
?nity compounds to antibodies are inherently gentle. this, in 
itself. did not ensure a successful outcome. Foremost, prior 
to the invention, it could not have been predicted with any 
degree of certainty that this photoa?inity reaction would 
occur under any conditions. because it was not known that 
antibodies comprise site or sites having a?inity for photo 
ai?nity compounds. in particular nucleotide and nucleoside 
photoai?nity compounds. and more particularly sites having 
high ai?nity for purine. azidopurine or similar heterocyclic 
base containing photoa?inity compounds. Moreover, even 
assuming that the existence such sites had been known. it 
could not have been predicted that reaction with such sites 
with compatible photoa?inity compounds would not have 
adversely affected antibody activity. most especially the 
ability of the antibody to bind antigen. For example. it was 
entirely possible that the nucleotide or nucleoside photoaf 
?nity compounds could have inserted in the antibody mol 
ecule at a site or sites within or su?iciently proximate to the 
antigen combining site. such that antigen binding activity 
was lost or substantially impaired. Alternatively, it was 
possible that the insertion of the nucleotide or nucleoside 
photoa?inity compounds into anu'body molecules could 
have induced conformational changes in the antibody mol 
ecule causing substantial reduction or loss of other antibody 
functions. However. quite surprisingly it has been found that 
nucleotide photoat?nity analogs readily attach to antibodies. 
in a site-specific manner. under conditions which do not 
result in substantial loss of antigen binding activity. 
5,693,764 
Thus, the invention in general provides a novel means for 
site-speci?cally photoattaching desired molecules to anti 
bodies nucleotide or nucleoside a?inity sites contained in the 
antibody. The invention further provides general methods 
for studying the function of these nucleotide and nucleoside 
a?inity sites, by binding di?erent nucleotide and nucleoside 
photoat‘?nity compounds to these sites and evaluating their 
effects on antibody functions, e. g., effector functions. 
As discussed in the Background of the Invention. methods 
for photoinsertion of nucleotide photoa?inity compounds, 
and speci?cally purine and purine analog photoal?nity com 
pounds in proteins having speci?c nucleotide binding sites 
have been reported in the literature. The subject invention 
embraces any set of reaction conditions which provides for 
the effective photoinsertion of a nucleotide or nucleoside 
photoa?inity compound, preferably a ptn’ine, azidopurine or 
similar heterocyclic base containing photoaf?nity analog. 
and most preferably an ATP- or GTP-analog photoa?inity 
compound, into an antibody molecule, which does not result 
in substantial loss of antigen binding. 
Suitable methods for attaching nucleotide photoa?inity 
analogs to proteins are described. e.g., in Potter & Haley, 
Meth. in EnzymoL, 91:613-633, (1983); Owens & Haley, J. 
Biol. Chem., 259: 14843-148 48, (1987);Atherton et al. Biol. 
of Reprvd, 32:155-171. (1985); Khatoon et al, Ann. of 
Neurology, 26:210-219, (1989); King et al, J. Biol. Chem, 
269210210-10218, (1989); Dholakia et al, J. Biol. Chem., 
264220638-20642. (1989); Campbell et al, Proc. Natl. Acad. 
Sci, 87:1243-1246, (1990); and Kim et al, J. Biol. Chem, 
265:3636-3641, (1990), which references are incorporated 
by reference in their entirety herein. 
Any antibody or antibody containing composition which 
e?’ectively binds nucleotide or nucleoside photoa?nity com 
pounds is within the scope of the present invention. This 
includes by way of example, polyclonal and monoclonal 
antibodies, recombinant antibodies, chimeric antibodies, 
bispeci?c antibodies, single chain antibodies, antibodies 
from di?’erent species (e.g., mouse, goat, rabbit, human, rat, 
bovine, etc), anti-idiotypic antibodies, antibodies of differ 
ent isotype (IgG, IgM, IgE. IgA. etc.), as well as fragments 
and derivatives thereof. (e.g., (Fab)2 fragments.) 
Optimal reaction conditions will vary dependent upon 
factors including the concentration of antibodies in the 
particular composition, the isotype and/or species origin of 
such antibodies, and the number and at?nity of nucleotide or 
nucleoside binding sites present on the particular antibodies. 
Suitable conditions can readily be determined by the skilled 
artisan by reference to the above-cited publications relating 
to nucleotide photoa?inity labeling of proteins, and the 
examples therein. 
The invention further embraces the use of any nucleotide 
or nucleoside photoa?inity compounds which e?ectively 
photoinserts into one or more nucleotide a?inity sites of a 
selected antibody under conditions which provide for the 
substantial retention of antigen binding activity. Moreover, 
if the antibody is to be used as a therapeutic agent, such 
conditions should preferably preserve other antibody 
functions. e.g.. etfector functions, comprised in the Fc 
portion of the antibody molecule (e. g., complement 
activation). 
The particular nucleotide or nucleoside photoa?inity 
compound may be directly reacted with an antibody, or it 
may ?rst be attached to another compound, e.g., a molecule 
having a desired elfector function or a reporter molecule, 
e.g., a radioactive label. 
Many nucleotide photoa?inity probes may be synthesized 
and used successfully. The photoafinity compounds of the 
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invention will preferably comprise adenine analogs. 
although guanine analogs can be substituted therefor. For 
example, purine binding sites may be effectively labeled by 
the following, and their 5'-mono-. di- and triphosphates: 
oligomers of a single azidoadenylyl species. such as, for 
example: 2~azido or 2-azidoadenylyl(2'-5‘)2-azidoadenylyl 
(2'-5')2-azidoadenosine; 2-azido or ?-azidoadadenosine; 
8-azidoadenylyl(2'-5')-8-azidoadenylyl(2'-5’)8 
azidoadenosine; 8-azidoadenylyl(2‘-5')- 8-azidoadenylyl(2' 
5')8-azidoadenylyl-(2'-5')8-azidoadenosine; 2.8 
diazidoadenylyl(2'-5‘)2,8-diazidoadenylyl(2‘-5’)2.8-diazido 
adenosine; 2.8-diazidoadenylyl(2'-5')2.8-diazidoadenylyl 
(2‘-5')-2.8-diazidoadenylyl(2’-5')2,S-diazidoadenosine; also 
oligomers of AMP and a single azidoadenylyl species. such 
as. for example: 2-azidoadenylyl(2'-S')2-(2'-5‘)adenosine; 
adenylyl(2'-5')8-azido adenyl(2’-5‘)8-azidoadenosine; also 
oligomers containing more than one azidoadenylyl species. 
such as, for example: 2-azidoadenylyl(2'-5')S-azidoadenylyl 
(2'-5')2-azidoadenosine; also oligomers resulting from any 
combination of the monomers AMP. 2-azido-AMP, 8-azido 
AMP and/or 2,8-diazido-AMP. provided that at least one 
such monomer incorporated into the oligomer is an azido 
AMP species. 
In addition photoa?inity compounds of the invention may 
also include photoactive coenzyme analogs of NAD", exem 
pli?ed by nicotinamide Z-azidoadenosine dinucleotide 
(2-azido-NAD+), or analogs of NADH. exempli?ed by 
nicotinamide Z-hydrazidoadenosine dinucleotide (2-azido 
NADH). 
Alternatively, guanine moieties can be de?ned in each of 
the exemplary compounds in place of the respective adenine 
moieties. Therefore, certain most preferred compounds of 
the present invention are synthesized from azidoguanosine 
5'-triphosphates or combinations thereof, or from azidogua 
nosine 5'-triphosphates and ATP. The latter provides a (2’ 
5')oligomer containing both guanylyl and azidoguanylyl 
moieties. 
Furthermore, photoa?inity compounds of the present 
invention may also include, for example, pyrimidine deriva 
tives. For instance, photoactive analogs of dUTP, such as 
5-azido-2'-deoxyuridine 5’-triphosphate (5-N3dUTP), may 
be synthesized from dUMP and provide a pathway for the 
synthesis of other useful S-subs?tnted uridine nucleotides. 
The 5—diazouridine nucleotides may, for example. serve as 
active-site-directed photoa?inity probes or as substrates for 
polymerizing enzymes to generate additional photoactive 
nucleic acids which remain stable to extremes of pH and 
which remain effective photolabeling reagents in the pres 
ence of reducing agents. Moreover. since the synthesis of 
5-N3dUTP employs mild conditions, it is also possible to 
synthesize homopolymers of 5-N3dUTP to provide single 
stranded photoactive DNA of de?ned length. Using 5N3UTP 
one can similarly produce photoactive RNA. 
Generalized methods for the synthesis of aryl azides 
include nucleophilic displacement of a bromine, chlorine or 
nine group by an azide ion or the addition of sodium azide 
to an acidic solution containing a diazotized primary aro 
matic amine. 
To date the most widely used 8-azidopurine is probably 
8N3cAMP. One of the advantages of 8N3cAMP is that in 
mammalian systems there are only two types of proteins that 
are known to bind cAMP with high a?inity. the cAMP 
phosphodiesterases and the regulatory subunits of the 
cAMP-dependent protein kinases. The photoprobes [32F] 
8N3cAMP and [32P]8N3ATP have been employed to study, 
for example, the mechanisms of action of cAMP-dependent 
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protein kinase. Photoactive analogs of GTP. e.g.. P2P] 
SNBGTP. have been developed to study. for example, tubulin 
polymerization. while photoactive analogs of UTP. e.g.. 
[32P]5N3dUTP have been generated to study, for example, 
the binding site of DNA binding proteins. 
Preferred compounds of the present invention are synthe 
sized from azidoadenosine 5'-triphosphates or combinations 
thereof. which provide a (2'-5‘)oligomer containing both 
adenylyl and azidoadenylyl moleties. Especially preferred 
photoa?inity compounds for use in the present invention 
include in particular Z-aZido-ATP. 8-azido-ATP and 
benzophcnone-A'I'P or other compounds which e?ectively 
compete with 2 or 8-azido-ATP for occupancy of the PRB 
binding domain. 
As noted. these photoa?inity compounds may further be 
attached to other molecules. e.g.. effector molecules or 
reporter molecules. provided that such molecules do not 
adversely a?’ect the ability of the photoa?inity compound to 
effectively photoinsert into nucleotide binding site or sites 
contained in the particular antibody. or provided that such 
molecules may be effectively attached to a nucleotide or 
nucleoside photoa?inity compound which has been bound to 
the particular antibody. 
Nonradioactive reporter molecules or labels can be 
divided into two categories: (i) chromogenic. ?uorogenic. or 
chemiluminescent dyes or (ii) ligands. Dyes are normally of 
from 8 to 40 carbon atoms. preferably from 9 to 30 carbon 
atoms. The dyes further normally contain from 1 to 10 
heteroatoms usually oxygen. nitrogen. or sulfur. and nor 
mally contain no halogen atoms or up to 10 halogen atoms 
usually iodine. bromine. chlorine. or ?uorine. 
Chromogenic dyes may include phenol sulfonephthalein 
and analogs of tetrazolium. 
Fluorogenic dyes may include ?uorescein isothiocyanate. 
dichlorotriazinylamino ?uorescein. morpholinorhodamine 
isothiocyanate. tetramethylrhodarnine isothiocyanate. and 
4-acetamido4-isothiocyanostilbene-Z with 2‘-disul.fonic 
acid. Fluorescent purine derivatives may also include, for 
example. the ?uorescent GTP analog 2'3'-O-(2.4.6 
trinitrocyclohexadienylo-idine)guanosine 5'-triphosphate 
('l‘N'P~GTP). or the equivalent ?uorescent ATP derivative 
('I‘NP-A'I‘P). 
Chemiluminescent dyes may include 5-amino-2.3 
dihydro-phthalazine-l.4-dione (lurninol). derivatives of iso 
lurninol and acridinium esters. 
Any ligand may be employed for which an appropriate 
receptor may be found to have satisfactory speci?city for the 
ligand. For example. the subject labeling method provides 
for the e?icient attachment of biotin to antibodies using the 
subject nucleotide or nucleoside photoaf?nity compounds. 
Speci?cally. this has been demonstrated by Western Blot 
(testing for reaction with avidin) using azido-ATP and 
azido—GTP compounds. 
Various methods or protocols may be employed in mea 
suring the amount of the labels. These protocols can include 
for example. radioimmunoassay (RIA). immunoradiometric 
assay (IRMA). sandwich IRMA. ?uoroimmunoassay (FIA). 
chemiluminescent assays. bioluminescent assays, and 
enzyme linked irmnunosorbent assays (ELISA) among oth 
ers. 
The labeled probe of the present invention can be used in 
any conventional hybridization technique. Hybridization 
formats which may be useful in the practice of the present 
invention include those in which the sample is immobilized 
on a solid support (solid-phase hybridization) and those 
wherein the species are all in solution (solution 
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hybridization). Solution hybridization is preferred in the 
present method. Another method of interest is the sandwich 
hybridization technique. 
Certain factors are considered when a unique biochemical 
macromolecular marker is identi?ed by means of a radio 
active photoa?inity label. as is the preferred method of the 
present invention. For example. consideration should be 
given to: (a) temperature of incubation and photolysis. (b) 
length of incubation and photolysis. (c) concentration of 
photoa?inity reagent. (d) binding affinity of protein for the 
reagent and natural ligands. (e) stability of the photoa?inity 
reagent in each particular system. (i) ionic strength. pH. 
cofactors. (g) protein concentration. (h) intensity of photo 
lyzing light. (i) quenching of reaction and separation of 
unused label. and (i) interpretation of results. Potter & Haley 
in Meth. in Enzymol. 91:613-633 (1983) provide a detailed 
account of preferred procedures for labeling a speci?c 
biochemical marker macromolecule in a sample with a 
photosensitive pln-ine triphosphate azide analog. 
Temperature of the photolysis reaction between the anti 
body sample and the selected photoaf?nity label can range 
from 0° C. to room temperature (25° C.) or above. However. 
the exchange rate between bound and unbound cAMP or 
8-N3cAMP approaches negligible levels at 0° C.. and is 
greatly increased at room temperature. Conversely. once 
8-N3cAMP is bound to the speci?c macromolecular marker. 
it may be cold trapped onto the protein by dropping the 
temperature to nearly 0'’ C. Therefore. the most preferred 
procedure includes preincubation of the components at room 
temperature. and photolysis in plates set on ice to reduce the 
temperature to approximately 0° to 4° C. By the present 
invention. the antibody containing sample is preferably 
incubated at room temperature with the radioactive photo 
a?inity probe for approximately 0.5 to 1.0 minutes. Most 
preferably the mixture is vortexed for 6 seconds followed by 
an additional 24 seconds of mixing. immediately followed 
by placing the sample on ice for photoactivation. 
The concentration of photoa?inity reagent must be com 
patible with the binding a?inity of the antibody which is to 
be labeled. Excessively high concentrations. however. can 
lead to undesirable nonspeci?c labeling which increases 
linearly with concentration. Best results can be obtained by 
experimentally determining the optimum concentran'on for 
photoincorporation. Directly related to the determination of 
concentration is the stability of the reagent. The stability of 
the reagent can be determined by thin-layer 
chromatography. e.g.. by ?uorescent cellulose thin-layer 
chromatography. 
Ionic strength, pH. oofactor. and metal ion concentrations 
can each a?ect antibody structure. and are readily adjusted 
by those skilled in the art to achieve optimal labeling 
conditions. The higher the protein content of the sample. the 
denser the solution becomes to light. Therefore. in a denser 
solution. less UV light reaches the photoreagent per unit of 
time. decreasing the rate of photoincorporation. Aggregation 
of the protein can also affect the binding time of the reagent 
to the protein. thereby increasing or decreasing photoincor 
poration. One must experimentally redeterrnine optimal 
photolysis time when changing protein concentration if 
maximum incorporation of the photolabel is desired. 
Detection of the labeled antibody occurs following an 
appropriate. predetermined incubation time to e?‘ect a 
reaction. and is calculated on the basis of the antibody 
sample and the selected photoa?inity probe. 
The intensity of the photolyzing light is such that maxi 
mum photoincorporation can be obtained in a minimum 
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amount of time without appreciable change in temperature 
or damage to the biological sample. Preferably the photoly 
sis is achieved at 254 nm with an ultraviolet light source. 
Ultraviolet (UV) light is essential for the activation of the 
photoprobe treated samples. but only a low intensity UV 
light is necessary. The intensity of the UV light can range 
from 180 to 800 nW/cm2 by conventional sources to 4000 
nW/cm2 and above when a high intensity source is used to 
achieve rapid photolysis. 
Photolysis times range from 15 seconds to 5 minutes and 
must be experimentally determined for each reaction sys 
tem. For lamps having intensi?es of 180-800 pW/cm“, the 
preferred photolysis time ranges from approximately 30 to 
120 seconds, most preferably, photolysis is effected in 
approximately 30 to 60 seconds. 
The distance of the light source from the sample is a 
determinative factor in the conditions of photolysis. A pre 
ferred method of the present invention uses an ultraviolet 
light source having su?icient intensity. about 6200 pwlcmz. 
positioned at a set distance, about 1 cm from the sample, for 
a time su?icient to e?’ect photoactivation. generally approxi 
mately 45 seconds. 
The labeled macromolecule is typically separated from 
the solution containing excess unbound sample and/or label 
by precipitation, although other recognized methods of 
protein puri?cation are possible. Recognized methods of 
precipitation include. but are not limited to addition of an 
effective protein precipitating agent such as trichloroacetic 
acid (TCA). perchloric acid (PCA), acetone, ammonium 
sulfate polyethylene-glycol (PEG) or the like to the sample. 
PCA or ammonium sulfate are the preferred precipitating 
agents in the present method. and PCA is the particularly 
preferred precipitating agent. 
The amount of precipitating agent is determined by the 
concentration of protein in the sample. The preferred con 
centration of the precipitating agent is that concentration 
which effectively precipitates the speci?c antibody from 
solution. The most preferred concentration of the precipi 
tating agent is that mount which effectively precipitates the 
previously activated, photolabeled antibody sample. 
The precipitating agent can be mixed with the sample as 
a dry batch addition or in a calculated equivalent liquid 
form. The required mixing time may vary with the nature of 
the agent selected and the size or concentration of the 
sample. However, the time required is that point after which 
essentially no additional protein is precipitated from the 
sample solution at the temperature selected. 
The precipitated antibodies may be separated from solu 
tion by any e?’ective means, such as centrifugation. sedi 
mentation or ?ltration. A preferred method of separation of 
the precipitated protein from the solution is by centrifuga 
tion at a su?icient speed and for a su?icient time to e?ec 
tively isolate the antibody proteins into a pellet. for example 
by centrifugation. However. the parameters vary with the 
nature of the antibody solution. 
To determine the effectiveness of the precipitation and 
separation procedures. both the pellet and the supernatant 
?uid are analyzed for protein content. 
The precipitated protein may be solubilized and any 
remaining reaction quenched by any etfective, lmown 
method. The determination of the solubilizing agent would 
depend on the ultimate method of identifying the speci?c 
nucleotide binding protein. Therefore, such agents could 
include, e.g., sodium dodecyl sulfate (SDS) or urea, and 
certain stabilizing agents. 
Any azide remaining after photolysis may be destroyed by 
the addition of dithiothreitol or its equivalent, and potential 
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phosphotransfer from the triphosphate derivative N3ATP or 
NSGTP may be inhibited by chelators such as EDTA. The 
preferred protein solubilizing agent is a detergent. particu 
larly SDS. most preferably in a protein solubilizing mix 
(PSM). such as described by Potter & Haley in Meth. in 
EnzymoL, 91:613-633 (1983) or by procedures standard to 
most published procedures. A particularly preferred concen 
tration of SDS in the mix is 10%, resulting in a concentration 
of SDS to the ?nal sample of 4 %. 
Solubilization can occur either at 0° C. or at higher 
temperatures without atfecting the results. However. solu 
bilization in the present invention is effective at room 
temperature. 
Upon solubilization, the protein sample is applied to a 
suitable support for separation of the protein fractions. 
Support materials could include. e.g., polyacrylamide gels, 
?lter paper, starch gels or blocks, cellulose or polyurethane 
foam. Any effective. known method of protein separation 
may be used, but preferably separation is by electrophoresis 
over denaturing or nondenaturing gels, or over a gradient of 
either type. In the present method, protein separation is 
usually by electrophoresis on a denaturing gel. 
The nature of the sample and the size of the speci?c 
nucleotide binding protein determine the concentration of 
the gel used, which in turn determines the time for separa 
tion and the electrical current which must be applied to best 
achieve protein separation. The protein fractions of the 
present invention most preferably may be separated by 
electrophoresis on an SDS-polyacrylamide gel (SDS-PAGE) 
or by isoelectric focusing (IEF) or on two dimensional 
systems (IEFxSDS-PAGE). Typically. the sample is frac 
tionated on a 10% polyacrylamide gel. run over a period of 
2V: to 3 hours, with constant amperage of 35 mA and an 
initial voltage of about 140 volts. Any standard electro 
phoresis equipment can be utilized. 
The resultant gels are exposed to X-ray ?lm and visual 
ized by autoradiography according to methods well known 
in the art. The gels can also be stained to determine the 
presence of the unique speci?c protein band or to ascertain 
that differences in the amount of photolabel incorporation 
are not due to drastic changes in the protein levels. Many 
known protein staining methods are widely recognized. e.g.. 
Coomassie Brilliant Blue (CBB) or silver staining. CBB is 
a commonly used stain that detects proteins based on a 
hydrophobic interaction between the proteins and the dye. 
Although any available staining method can be used which 
effectively distinguishes the speci?c nucleotide binding 
protein, CBB is the fastest and most economical for the 
present method. 
Most preferably, each completed SDS-PAGE gel is 
stained with an effective amount of CR8 to stain the selected 
protein fragments. However. many times proteins can be 
detected by photolabelling that cannot be detected by any 
protein staining procedure. In particular, the completed gel 
is immersed in a 10% CBB (wlv) solution for about 1 hour. 
Then the gel is destained in a solution to effectively remove 
excess stain. Particularly preferred is a destaining solution of 
5% acetic acid and 10% isopropyl alcohol applied for 10-18 
hours. 
Finally, the speci?c binding protein fragments may be 
visualized by standard autoradiography techniques. The use 
of an intensifying screen effectively accelerates the visual 
ization process of autoradiography. By the method of the 
present invention, the stained gel is dried. and then exposed 
to DuPont Cronex 4 X-ray ?lm. The autoradiographic pro 
cedure is for variable time periods depending on the speci?c 
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activity of the probe photoinserted into the proteins of each 
experimental sample. Alternately. if maintained at —70° C., 
the gel can be subjected to autoradiographic procedures 
while still in the gel state. 
The amount of protein, as well as the radioactivity incor 
porated into each protein, can be quanti?ed by known 
methods including, but not limited to, densitometric scans of 
the exposed X-ray ?lm, or of the stained gel, or by liquid 
scintillation spectrometry of the protein band following 
excision from the gel. 
As discussed supra, another application of the subject 
a?inity labeling method comprises the attachment of desired 
effector molecules to antibodies, wherein these molecules 
are site-speci?cally attached to a photoa?inity site, in par 
ticular at a site or sites having high a?inity for purine. 
azidopurine and other similar heterocyclic bases, and more 
particularly ATP- or GTP-analog photoa?inity compounds. 
This is an important application of the subject method given 
that the present method of attachment is site-speci?c and 
does not substantially affect the architecture of the antibody 
molecule or its ability to bind antigen. Therefore. effector 
molecule containing antibodies produced by this method 
will bind to a target more effectively, e.g., a tumor cell 
expressing the corresponding antigen Moreover, non 
speci?c binding should be minimized which is highly sig 
ni?cant if the antibody-effector conjugate is to be used as a 
therapeutic agent, since this should minimize systemic tox 
icity. 
The subject method is applicable for site-speci?cally 
attaching any eifector molecule which, when attached to a 
nucleotide photoaf?nity compound does not adversely atfect 
the ability of the resultant effector-nucleotide photoa?inity 
compound to site-speci?cally attach to a nucleic acid bind 
ing site comprised on the antibody molecule. or which may 
be site-speci?cally attached to a nucleotide photoa?inity 
compound which has been previously been site-speci?cally 
bound to a nucleic acid binding site on an antibody. 
As noted previously, an e?iector molecule is broadly 
de?ned as any moiety which comprises a desired functions, 
e.g., a particular biological or chemical activity. In the 
preferred embodiment, the e?‘ector will comprise an activity 
which enables the etfector-antibody conjugate to be used as 
a therapeutic or an imaging agent, e.g., for treating or 
visualizing tumors. 
Examples of effector molecules within the scope of the 
invention include by way of example cytotoxic moteties 
such as enzymatically active toxins and fragments thereof 
such as diphtheria toxin, Pseudomonas exotoxin, ricin A. 
abrin A, modeccin A. alpha-sarcin, Alevritesfoniii proteins, 
dianthin proteins, Phytolacca americana proteins (PAPI, 
PAPII. PAPII) , Mornardica charantia inhibitor, carcin, 
erotin. Sapanaria o?icinalis inhibitor, gelonin, mitogellin. 
restrictocin, phenomycin , and enomycin antitumor agents 
such as daunomycin, daunorubicin, methotrexate, cytokines 
such as interleukins (IL-l. lL-2, etc.). interferons (0t 
interferon, B interferon, 'y interferon), colony stimulating 
factors, tumor necrosis factors, and lymphotoxins, enzymes, 
radionuclides, chelating agents, growth factors, polynucle 
otides (DNA, RNA, antisense DNA or RNA mixtures 
thereof) heavy metal isotopes, as well as other moieties 
having therapeutic or diagnostic utility. 
The effector moieties may be directly attached to the 
photoal?nity compound, or attachment may be effected 
using a bifunctional coupling agent. Examples of such 
reagents include by way of example SPDP, II‘, dimethyl 
adipimidate HCl , active esters such as disuccinirnidyl 
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suberate. aldehydes such as glutaraldehyde, bis-azido 
compounds, bis-diazonium derivatives such as bis-(p 
diazonium benzoylyethylenediamine, diisocynates such as 
tolylene 2.6-diisocyanate, and bis-active ?uorine com 
pounds such as 1,5 -di?uoro-2,4 -ditrobenzene. 
Particular types of effector molecules considered to have 
preferred application in the invention include radiolabels 
and chelating agents, in 'cular triphosphate chelated 
heavy metals such as 111In + (which has known application 
as a diagnostic imaging agent), nucleic acids having utility 
in gene therapy or antisense therapy, enzymes having diag 
nostic or therapeutic utility, and toxins. 
Effector molecules may be attached to the photoa?inity 
compound. preferably a purine or azidopurine photoa?inity 
compound and more preferably an AI'P- or GTP-analog 
photoa?inity compound, by various means of attachment 
The selection of suitable means of attachment will depend 
upon the particular effector and functional groups available 
for covalent attachment or complexation to the particular 
nucleotide or nucleoside photoa?inity compound. 
Preferably, such chemical attachment will occur under mild 
conditions to preserve the activity of the antibody and 
effector. 
For example, proteins may be attached to the subject 
purine or purine derivative containing photoa?inity probes, 
and more particularly AI'P- and GTP-analog photoa?inity 
compounds, by converting the cis-hydroyl group on the 
ribose under gentle conditions to a dialdchyde. The dialde 
hyde will then form a Schitf's base with amino groups of 
proteins or other amino group containing compounds. 
Also, the subject photolabeled antibodies have been 
shown to have very high a?inity to polylysine because of the 
presence of a highly negatively charged triphosphate or 
tetraphosphate. Consequently, this will permit established 
procedures to be used to couple a polylysine containing 
polynucleotide. e.g., DNA, RNA or complexes thereof, to 
the photolabeled antibody. This will further enable the 
polynucleotide to be site-speci?cally targeted to an antigen 
expressing target, e.g., a tumor cell or a site of infection. 
Additionally, it has been shown that the subject nucleotide 
photoai?nity compounds attach under gentle conditions to 
heavy metals, e.g., triphosphate chelated metals, in particu 
lar 111Ina", wherein this reaction may be e?‘edzed before or 
after the photoa?inity compound is attached to the antibody. 
Preferably, the photoa?inity compounds will comprise ATP 
or GTP-analog photoa?inity compounds, and most prefer 
ably Z-aZidO-AH‘P, 8-azido-ATP or benzophenone-ATP. 
When used in vivo for therapy, the effector-antibody con 
jugates of the invention will be administered in therapeuti 
cally effective amounts. This will of course depend upon 
factors including the specific disease condition being 
treated, the condition of the patient, the antigen binding 
properties of the antibody (a?inity, avidity of antibody for 
antigen), and the particular effector molecule that is attached 
to the antibody. Particular disease conditions contemplated 
for treatment include, e.g., cancers, infectious diseases, and 
genetic disorders. 
The subject photoa?inity compound antibody-conjugates 
will normally be administered parenterally, when possible at 
the target, e.g., a tumor, at particular organ, or a site of 
infection. 
For parenteral administration these conjugates will be 
formulated in a unit dosage injectable form (solution. 
suspension, emulsion) in association with a pharmaceuti 
cally acceptable parenteral vehicle. Such vehicles are inher 
ently nontoxic. and non-therapeutic. Examples of such 
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vehicles are water, saline. Ringer’s solution, dextrose 
solution, and 5% human serum albumin. Nonaqueous 
vehicles such as ?xed oils and ethyl oleate may also be used. 
Liposomes may be used as carriers. The vehicle may contain 
minor amounts of additives such as substances that enhance 
isotonicity and chemical stability, e.g.. buifers and preser 
vatives. The antibody conjugates will typically be formu 
lated in such vehicles at concentrations of about 1 mg/ml to 
10 mg/ml. 
The selection of an antibody subclass for therapy will 
depend upon the nature of the antigen. For example. an IgM 
may be preferred in situations where the antigen is highly 
speci?c for the target and rarely occurs on normal cells. 
However. where the antigen is also expressed in non 
targeted. e.g., normal tissues. an IgG antibody may be 
preferred. 
The following examples are o?ered to more further 
illustrate the nature, but are not to be construed as limiting 
the scope thereof. 
EXAMPLES 
Standard procedures and reagents were used in accor 
dance with Maniatis et al (1982) Molecular Cloning: A 
Laboratory Manual. Cold Spring Harbor Laboratory, New 
York. Speci?c techniques for the photoa?inity labeling of 
speci?c nucleotide binding sites with purine phosphate azide 
analogues were used in accordance with Potter & Haley. 
Meth. in EnzymoL, 90:613-633 (1983). 
Example 1 
Labeling Ef?ciency of [Wm-8+1. ATP for SIC5 
Antibody 
The SIC5 antibody comprises an anti-B cell lymphoma 
idiotype antibody which is useful for evaluating the e?i 
ciency of labeling by idiotype solid phase assays and minor 
cell binding as well as in tumor imaging. Therefore. given 
these inherent properties. this antibody was selected to 
determine labeling e?iciency of the subject method. 
In particular. 3 pg of SIC5 antibody in 30 mL of pho 
tolysis bu?er was photolyzed with increasing concentrations 
of [732P]-8-N3 ATP and then separated by SDS-PAGE. 32P 
incorporation was detected by autoradiography and quanti 
?ed by scanning on Optical Imaging Acquisition Analysis 
(Ambis. Inc.). Photoinoorporatiou was quantitatively con 
?rmed by cutting the appropriate bond and determining 
radioactivity by liquid scintillation counting. These results 
are set forth in FIG. 1. Based upon these results. it can be 
clearly seen that the radioactive probe is covalently attach 
ing to both antibody heavy and light chains. It can further be 
seen that there is a de?ned saturating concentration of probe 
at about 200 pm for both chains. This saturation plateau 
provides strong evidence that there exists a unique and 
limited number of a?inity sites of the antibody which are 
bound by the ["f‘zPHi-N3 ATP compound. 
Example 2 
Determination of the Speci?city of the Antibody 
Nucleic Af?nity Site 
In order to identify which pan of the [7”P1-8-N, ATP 
probe is binding the antibody. i.e.. the speci?city of the 
antibody a?inity site. the following experiment was con 
ducted 
The SIC5 antibody was again labeled. but in this example 
labeling was performed in the presence of increasing 
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amounts of tree ATP. Speci?cally. 3 pg of the SIC5 antibody 
was photolyzed in the presence of 200 pm ['y:‘2P]-8-N3 ATP 
using concentrations of ATP ranging from 0 to 700 pm. The 
labeled protein was again separated by SDS-PAGE; and 
radioactivity determined by liquid scintillation counting. 
These results are shown in FIG. 2. 
Based on the results contained therein. it can be clearly 
seen that ATP inhibits labeling of both the heavy and light 
antibody chains of the SIC5 antibody. The results further 
indicate that 50 % of inhibition of labeling occurs at around 
a 350 um ATP concentration. Thus. these results provide 
further evidence that the SIC5 antibody comprises one or 
more sites having speci?c a?inity for the lynPHi-N3 ATP 
compound. 
Example 3 
Labeling of the SIC5 Antibody Using {7”P1-8-N3 
ATP Benzophenone 
Another photoactivating probe. [32P]-8-N3 ATP 
benzophenone. was tested to determine its ei?cacy for 
labeling the SIC5 antibody. This experiment was conducted 
under substantially the same conditions as Example 1. 
except that [\(32P]-8-N3 benzophenone was substituted for 
[Y”P]-8-N3. Incorporation of label into the SIC5 heavy and 
light chains were then measured. It was demonstrated that 
saturation was achieved at about 100 mM concentration of 
probe. 
These results indicate that the SIC5 antibody comprises 
one or more a?inity sites which are eifectively labeled by the 
[y32P]-8-N3 ATP benzophenone compound. and that the 
SIC5 antibody may be e?edively labeled using dill‘erent 
nucleotide photoactivating probes. 
Example 4 
A?‘inity of SIC5 Antibody Site for Oligonucleotides 
The a?inity of the SIC5 antibody for oligonucleotides was 
also evaluated using oligonucleotides of different length. to 
block photolabeling with an ATP probe. Speci?cally. 3 pg of 
the SIC5 antibody was incubated for two hours at 4° C. with 
1 mg of a 24-mer. 30-mrn'. 33-mer. 58-mer. followed by 
incubation with 200 pm of [Yi2P]-8-N3 ATP for 60 seconds. 
photolysis for 60 seconds, followed by separation of protein 
using SDS-PAGE. Photoincorporation was again quantita 
tively determined by cutting the appropriate band and deter 
mining 32F radioac?vity by liquid scintillation counting. 
These results are contained in FIG. 3. Based on these results. 
it would appear that blocking e?iciency increases with the 
length of the oligonucleotide. This provides further evidence 
in support of the existence of one or more sites on the 
antibody having speci?c a?inity for ATP photoa?inity 
probes. Additional experiments are planned using oligo 
nucleotides of speci?c sequences to further analyze the 
sequence speci?city of the a?inity site(s). 
Example 5 
Effect of Labeling on Antigen Binding 
The effect of labeling on antigen binding and antigen 
speci?city was determined using the 3H1 anti-idiotype 
antibody. for which an idiotype is readily available. The 
binding of 3H1 to idiotype was tested in a solid phase 
binding assay (ELISA) using isotope labeled 3H1 in the 
presence of unlabeled 3H1 antibody to inhibit binding. 
In particular. the idiotype antibody was used as antigen for 
plate coating (500 mglwell). The same mount of labeled 3H1 
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(311g) was mixed with different mounts of the unlabeled 
antibody and incubated for two hours at 25° C. After 
incubation. the wells were washed. dried, out and 32F 
radioactively counted by liquid scintillation. The SD10 
antibody was used as the non-speci?c cell inhibitor. 
These results. using different speci?c mounts of unlabeled 
antibody ranging from 0 to 10 pg are shown in FIG. 4. It can 
be clearly seen from these results that the cold (unlabeled) 
3H1 antibody inhibits the binding of isotope labeled 3H1. 
Example 6 
Cell-Surface Competition Binding of Labeled SD10 
Antibody 
The binding of isotope labeled anti-B cell lymphoma 
idiotypic antibody to live tumor cells was tested. 
Speci?cally. 1o6 SU-DHL-4 cells were incubated with dif 
ferent mounts of unlabeled antibody and the same mount of 
labeled antibody (3 mg/tube) for 30 minutes at 4° C. Cells 
were then washed using 20 % fetal calf serum (FCS) 
medium). Binding of ynP-labeled antibody was detected by 
liquid scintillation counting. 
These results are contained in FIG. 5. It can be clearly 
seen that the unlabeled antibody etfectively inhibits binding 
of the isotope labeled antibody to tumor cells. 
Example 7 
Characterization of Labeled Antibodies by 
Isoelectr'ic Focussing 
Labeled antibodies were also characterized by isoelectric 
focusing. A representative isoelectric focusing pattern of a 
labeled and unlabeled antibody is found in FIG. 6. 
Isoelectric focusing was e?’ected at a pH ranging from 3 
to 10 using SICS antibodies which had been photolabeled 
with increasing concentrations of [*f’Pl-S-N3 ATP. The 
isoelectric focusing standards used were: 
A=cytochrome C (pI 9.6). B=equine myoglobin (pI 7.0). 
C=bovine carbonic anhydrase (pI 6.0). D =phycocyanin 
(pI 4.65) (lane 10). 
The unlabeled antibody is shown in lane 1. 
SICS antibody (5 pg) was photolyzed by 3.125 pm (lane 
9). 6.25 pm (lane 8). 12.5 mm (lane 7). 25 pm (lane 6). 50 pm 
(lane 5). 100 pm (lane 4). 200 pm (lane 3). and 400 pm (lane 
2) [7”Pl-8-NS ATP. 
Example 8 
Labeling. of Antibodies of Di?’erent Species and 
Isotype Using [7”P1-8-N; ATP 
In this experiment. antibodies of different species. origin 
and isotype were labeled with [y32P]-8-N3 ATP. Speci?cally. 
rmn-ine. goat, human and rabbit antibodies were labeled with 
[f2Pl-8-N3 ATP. Labeling was again eifected substantially 
in accordance with Example 1. The same amount (3 pg) of 
the respective antibodies [murine monoclonal IgGl. SD10 
(lane 1). murine myeloma IgGl (lane 2). murine myeloma 
IgA (lane 3). goat Ig (lane 4). goat (Fab)2 fragments (lane 5). 
human myeloma IgGl K (lane 6). human myeloma IgGl 1 
(lane 7), human myeloma IgM (lane 8). murine monoclonal 
IgM (lane 9). murine monoclonal IgG2b. SIC5 (lane 10)] 
was photolyzed in the presence of 200 pm [y”P]-8-N3 ATP 
and separated by 8-16% gradient SDS-PAGE. Following 
electrophoresis. the gel was stained with Coomassie Blue, 
dried and autoradiographed. These results are contained in 
FIG. 7. 
10 
20 
25 
35 
40 
45 
50 
SS 
65 
20 
The results indicate that these different antibodies effec 
tively incorporate the label into the heavy and light chains 
and that the amount of incorporation varies with the di?erent 
antibodies. It can further be seen that a Fab fragment (goat 
Ig is Fab fragment) is etfective labeled. 
Thus. these results indicate that nucleotide a?inity bind 
ing sites suitable for photoa?inity nucleotide labeling are 
comprised on antibodies of different species. origin and an 
antibody of different isotype. Moreover. these results indi~ 
cate that antibody fragments. as well as intact antibodies 
may be effectively labeled using nucleotide photoa?inity 
probes. 
While the invention has been described in the terms of 
various preferred embodiments. the skilled artisan will 
appreciate that various modi?cations. substitutions. 
omissions, and changes may be made without departing 
from the spirit thereof. Accordingly. it is intended that the 
scope of the present invention be limited solely by the scope 
of the following claims. including equivalents thereof. 
What is claimed is: 
l. A nucleotide photoa?inity compound-antibody conju 
gate produced by reacting an antibody-containing sample 
with an effective amount of a nucleotide photoaf?nity com 
pound under conditions which provide for the site-speci?c 
photoinsertion of said nucleotide photo-affinity compound at 
one or more nucleotide binding sites in the antibody con 
tained in the sample. 
2. The nucleotide photoa?inity compound-antibody con 
jugate of claim 1. wherein said nucleotide photoa?inity 
compound is an ATP- or GTP-analog photoa?inity com 
pound. 
3. The nucleotide photoa?inity compound-antibody con 
jugate of claim 1. wherein the nucleotide photoaf?nity 
compound site-speci?cally attaches to one or more sites 
having high at?nity for purine. azidopun'ne or heterocyclic 
bases having a similar structure to purine. 
4. The nucleotide photoa?inity compound-antibody con 
jugate of claim 2, wherein the ATP- or GTP-analog is 
selected from the group consisting of 2-azido-ATP, S-azido 
ATP and benzoylphenone-ATP. 
5. The nucleotide photoa?inity compound-antibody con 
jugate of claim 1. wherein said antibody is selected from the 
group consisting of polyclonal antibodies. monoclonal 
antibodies. recombinant antibodies. chimeric antibodies. 
bispeci?c antibodies and fragments thereof. 
6. The nucleotide photoat?nity compound-antibody con 
jugate of claim 1. wherein the nucleotide photoa?inity 
compound is covalently bound or complexed to a reporter. 
7. The nucleotide photoa?inity compound-antibody con 
jugate of claim 6. wherein the reporter is selected from the 
group consisting of radiolabels. enzymes. chromophores. 
polynucleotides. and ?uorochromes. 
8. The nucleotide photoa?‘inity compound-antibody con 
jugate of claim 6. wherein the reporter is a radiolabel. 
9. The nucleotide photoat?nity compound-antibody con 
jugate of claim 1, wherein site-speci?c photoinsertion is 
e?‘ected using ultraviolet light. 
10. The nucleotide photoa?inity compound-antibody con 
jugate of claim 1. wherein the nucleotide photoaf?nity 
compound is covalently bound to or complexed to an 
etfector molecule. 
11. The nucleotide photoa?nity compound-antibody con 
jugate of claim 10. wherein the eifector is selected ?om the 
group consisting of proteins DNA. RNA. DNA or RNA 
containing complexes toxins. cytokines. chelatin agents. and 
radiolabels. 
12. The nucleotide photoa?inity compound-antibody con 
jugate of claim 10. wherein the effector is a heavy metal. 
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13. The nucleotide photoa?inity compound-antibody con- 15. The nucleotide photoaf?nity compound-antibody con 
jugate of claim 12. wherein the heavy metal is radioactive. jugate of claim 13, wherein the radioactive heavy metal is 
14. The nucleotide photoa?inity compound-antibody con- 111In“. 
jugate of claim 12, wherein the heavy metal is iron or 
mercury * * * * * 
